Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 5Head & Neck 4Genitourinary 3Lymphoid 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Other 1Gastrointestinal 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Carcinoma, Renal Cell 1Adenocarcinoma, Follicular 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Rosiglitazone × Genitourinary × Clear all
NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

NCT00084578 2013-07-15

Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder

Fox Chase Cancer Center

Phase NA Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00182052 2013-05-23

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Massachusetts General Hospital

Phase 3 Completed
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡